New combo shrinks untreatable liver tumors in early trial
NCT ID NCT05348811
First seen Jan 09, 2026 · Last updated May 18, 2026 · Updated 21 times
Summary
This study tested a combination of three treatments—chemotherapy directly into the liver (HAIC), a targeted drug (donafenib), and an immunotherapy (sintilimab)—in 25 people with bile duct cancer that could not be removed by surgery. The goal was to see if the combination could shrink tumors and control the disease. Early results suggest the approach may help some patients, but more research is needed to confirm long-term benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongda Hospital, Southeast University
Nanjing, Jiangsu, 210009, China
Conditions
Explore the condition pages connected to this study.